SCHEMBL118977

SCHEMBL118977

Cc1ccc(S(=O)(=O)C#N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.54
ALDH1A1 P00352 5/20 0.52
TDP1 Q9NUW8 3/20 0.52
MAPT P10636 2/20 0.52
CYP3A4 P08684 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
NPC1 O15118 1/20 0.52
NFKB1 P19838 1/20 0.52
S100A4 P26447 1/20 0.52
MTOR P42345 1/20 0.52
RAB9A P51151 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MEN1 O00255 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28653034 0.90 GAA (0.45) GAAALDH1A1TDP1MAPTCYP3A4
SCHEMBL27381634 0.82 GAA (0.42) GAAALDH1A1TDP1MAPTCYP3A4
SCHEMBL28577615 0.80 GAA (0.59) GAAALDH1A1TDP1MAPTCYP3A4
SCHEMBL6585722 0.78 GAA (0.56) GAAALDH1A1TDP1MAPTCYP3A4
P-Xylene SCHEMBL11183319 0.77 ALDH1A1 (0.48) GAAALDH1A1TDP1MAPTCYP3A4
SCHEMBL14018160 0.76 MMP2 (0.45) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL1721592 0.76 GAA (0.54) GAAALDH1A1TDP1MAPTCYP3A4
SCHEMBL12017078 0.76 CA2 (0.50) MAPK1CA1CA2CA12CA9
SCHEMBL9273311 0.76 ALDH1A1 (0.54) ALDH1A1CYP3A4NPC1MEN1HPGD
SCHEMBL360697 0.76 GAA (0.54) GAAALDH1A1TDP1MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1081 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215019-A1 ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-07-03 US claimed
CN-113549120-B Method for preparing ribonucleoside 吉利德科学公司 2025-04-29 CN claimed
CN-115340503-B Synthesis method and application of chiral semicorrinoid compound 四川师范大学 2024-12-24 CN claimed
CN-117645581-A Method for synthesizing series of functional groups of photocatalytic inert C (sp 3) -H bond 浙江工业大学台州研究院 2024-03-05 CN claimed
WO-2023183757-A2 ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-09-28 WO claimed
CN-116444330-A Addition product of alkyl free radical and capture reagent, addition method and application thereof 深圳湾实验室坪山生物医药研发转化中心 2023-07-18 CN claimed
CN-115340503-A Synthetic method and application of chiral hemicorrin compound 四川师范大学 2022-11-15 CN claimed
CN-111233869-B Novel compound for preparing Rudexilvir key intermediate and preparation method thereof 杭州新博思生物医药有限公司 2022-09-16 CN claimed
EP-4026837-A1 PROCESS FOR PRODUCING 2,5-DIAMINO-2,5-DIDEOXY-1,4:3,6-DIANHYDROHEXITOL Covestro Deutschland AG (DE) 2022-07-13 EP claimed
CN-110165175-B High-nickel ternary cathode material and preparation method and application thereof 合肥国轩高科动力能源有限公司 2022-03-11 CN claimed
US-20080214528-A1 ANTI-INFECTIVE AGENTS ABBVIE INC. 2008-09-04 US claimed
WO-2008011337-A1 HCV INHIBITORS ABBOTT LABORATORIES (US) 2008-01-24 WO claimed
EP-0926136-B1 Process for producing and method of crystallizing 2-azabicyclo(2.2.1)hept-5-en-3-one KURARAY CO (JP) 2004-05-12 EP claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0926136-A2 Process for producing and method of crystallizing 2-azabicyclo(2.2.1)hept-5-en-3-one KURARAY CO., LTD. (JP) 1999-06-30 EP claimed
EP-0713490-B1 C-22 RING STABILIZED RAPAMYCIN DERIVATIVES AMERICAN HOME PROD (US) 1998-02-25 EP claimed
EP-0303636-B1 A PROCESS FOR THE PREPARATION OF PYRETHROID TYPE ESTER COMPOUNDS LUCKY, LTD. (KR) 1992-05-13 EP claimed
EP-0196707-B1 19-NOR STEROIDS SUBSTITUTED AT POSITIONS 11 AND 17 AND OPTIONALLY AT POSITION 2, THEIR PREPARATION, THEIR USE AS MEDICAMENTS, COMPOSITIONS CONTAINING THEM AND INTERMEDIATES OBTAINED ROUSSEL-UCLAF (FR) 1989-09-27 EP claimed
EP-0097572-B1 19-NOR STEROIDS SUBSTITUTED AT POSITION 11 AND OPTIONALLY AT POSITION 2, THEIR PREPARATION, THEIR UTILIZATION AS MEDICAMENTS, COMPOSITIONS CONTAINING THEM AND INTERMEDIATES OBTAINED ROUSSEL-UCLAF (FR) 1986-11-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215019-A1 ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS BMP2, BMP4, DCX GAA 4189/4885ALDH1A1 1282/4885TDP1 4142/4885
US-20080214528-A1 ANTI-INFECTIVE AGENTS NQO2, RSU1, RRS1 GAA 3089/4885ALDH1A1 1406/4885TDP1 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.